We rank companies based on fund manager, research analyst and news sentiment
YMAB stock icon

Y-mAbs Therapeutics
YMAB

$14.91
3.76%
 

About: Y-mAbs Therapeutics Inc is a commercial-stage biopharmaceutical company. It is mainly engaged in the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. DANYELZA, is the first FDA-approved product of the company which is a recombinant humanized immunoglobulin G, subtype 1k, or IgG1k, monoclonal antibody or mAb that targets ganglioside GD2, which is expressed in various neuroectoderm-derived tumors and sarcomas.

Employees: 100

0
Funds holding %
of 6,474 funds
0
Analysts bullish %
of 4 analysts
News positive %

Fund manager confidence

Based on 2023 Q4 SEC filings by fund managers ($100M+ AUM)

29% more capital invested

Capital invested by funds: $107M [Q3] → $138M (+$30.7M) [Q4]

16% more repeat investments, than reductions

Existing positions increased: 37 | Existing positions reduced: 32

1.32% more ownership

Funds ownership: 45.07% [Q3] → 46.38% (+1.32%) [Q4]

0% more funds holding in top 10

Funds holding in top 10: 1 [Q3] → 1 (+0) [Q4]

4% less funds holding

Funds holding: 98 [Q3] → 94 (-4) [Q4]

27% less first-time investments, than exits

New positions opened: 11 | Existing positions closed: 15

30% less call options, than puts

Call options by funds: $10.9K | Put options by funds: $15.7K

Research analyst outlook

4 Wall Street Analysts provided 1 year price forecasts over the past 6 months

Low target
$11
26%
downside
Avg. target
$21
41%
upside
High target
$26
74%
upside

4 analyst ratings

positive
100%
neutral
0%
negative
0%
Canaccord Genuity
Bill Maughan
74%upside
$26
Buy
Maintained
4 Mar 2024
BMO Capital
Etzer Darout
74%upside
$26
Outperform
Maintained
4 Mar 2024
HC Wainwright & Co.
Robert Burns
41%upside
$21
Buy
Maintained
20 Feb 2024
HC Wainwright & Co.
Robert Burns
26%downside
$11
Buy
Reiterated
15 Nov 2023

Financial journalist opinion